Surrogate Endpoints Show Mixed Value in Breast Cancer Trials

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete response, invasive disease-free survival, and overall survival were analyzed.
Medscape Medical News